[PDF][PDF] Comparison of Gefitinib Monotherapy and Chemotherapy with Cisplatin and Gemcitabine in
KC Chen, GC Chang, TY Yang, MC Yin - saints-united.com
Background: Lung cancer is the leading cause of cancer death in the world. In advanced
NSCLC, chemotherapy is the standard treatment strategy, but it has unfavorable side effects …
NSCLC, chemotherapy is the standard treatment strategy, but it has unfavorable side effects …
Pharmacokinetic evaluation of gefitinib when administered with chemotherapy
LA Hammond - Clinical Lung Cancer, 2003 - Elsevier
Gefitinib is a small-molecule agent specifically targeted to inhibit the epidermal growth factor
receptor–tyrosine kinase (EGFR-TK). Tumor responses have been achieved with gefitinib …
receptor–tyrosine kinase (EGFR-TK). Tumor responses have been achieved with gefitinib …
Analysis of the response and toxicity to gefitinib of non-small cell lung cancer
J Konishi, K Yamazaki, I Kinoshita, H Isobe… - Anticancer …, 2005 - ar.iiarjournals.org
Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth
factor receptor (EGFR), which had antitumor activity in patients with previously treated non …
factor receptor (EGFR), which had antitumor activity in patients with previously treated non …
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non–small-cell lung …
VA Miller, DH Johnson, LM Krug, B Pizzo… - Journal of clinical …, 2003 - ascopubs.org
Purpose: Gefitinib is an oral agent that inhibits the tyrosine kinase of the epidermal growth
factor receptor. In phase I trials gefitinib was well tolerated and antitumor activity was seen in …
factor receptor. In phase I trials gefitinib was well tolerated and antitumor activity was seen in …
Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 1
G Giaccone, RS Herbst, C Manegold… - Journal of Clinical …, 2004 - ascopubs.org
Purpose The purpose of this study was to determine whether the addition of the epidermal
growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca …
growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca …
Gefitinib Therapy for Advanced Non–Small-Cell Lung Cancer
CY Liu, S Seen - Annals of Pharmacotherapy, 2003 - journals.sagepub.com
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and toxicity of
gefitinib in non–small-cell lung cancer (NSCLC). DATA SOURCES: Primary literature search …
gefitinib in non–small-cell lung cancer (NSCLC). DATA SOURCES: Primary literature search …
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib
H Asahina, S Oizumi, A Inoue, I Kinoshita, T Ishida… - Oncology, 2011 - karger.com
Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We
conducted the first prospective phase II study of gefitinib readministration in previous …
conducted the first prospective phase II study of gefitinib readministration in previous …
Gefitinib in non-small cell lung cancer
K Tamura, M Fukuoka - Expert opinion on pharmacotherapy, 2005 - Taylor & Francis
Gefitinib (IressaTM), an orally-active tyrosine kinase inhibitor of the epidermal growth factor
receptor (EGFR), is the first approved molecular-targeted drug for the management of …
receptor (EGFR), is the first approved molecular-targeted drug for the management of …
Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study
YM Chen, RP Perng, CM Tsai - Journal of chemotherapy, 2005 - Taylor & Francis
Gefitinib has shown activity in the treatment of non-small-cell lung cancer (NSCLC) patients
who failed previous platinum-based combination chemotherapy and/or taxane treatment …
who failed previous platinum-based combination chemotherapy and/or taxane treatment …
Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer
JE Frampton, SE Easthope - Drugs, 2004 - Springer
Gefitinib (Iressa™), the first commercially available epidermal growth factor receptor-tyrosine
kinase (EGFR-TK) inhibitor, is indicated in the management of patients with locally …
kinase (EGFR-TK) inhibitor, is indicated in the management of patients with locally …